Abstract:The metamorphic protein XCL1 switches between two distinct native structures with different functions in the human immune system. This structural interconversion requires complete rearrangement of all hydrogen bonding networks, yet fold-switching occurs spontaneously and reversibly in solution. One structure occupies the canonical α-β chemokine fold and binds XCL1's cognate G-protein coupled receptor, while the other structure occupies a dimeric, all-β fold that binds glycosaminoglycans and has antimicrobial activity. Both of these functions are important for the biologic role of XCL1 in the immune system, and each structure is approximately equally populated under near-physiologic conditions. Recent work has begun to illuminate XCL1's role in combatting infection and cancer. However, without a way to control XCL1's dynamic structural interconversion, it is difficult to study the role of XCL1 fold-switching in human health and disease. Thus, a molecular tool that can regulate the fractional population of the two XCL1 structures is needed. Here, we find by heparin affinity chromatography and NMR that an engineered XCL1 variant called CC5 can trigger a dose-dependent shift in XCL1's metamorphic equilibrium such that the receptor binding structure is depleted, and the antimicrobial structure is more heavily populated. This shift likely occurs due to formation of XCL1-CC5 heterodimers in which both protomers occupy the β-sheet structure. These findings lay the groundwork for future studies seeking to understand the functional role of XCL1 metamorphosis, as well as studies screening for a drug-like molecule that can therapeutically target XCL1 by tuning its metamorphic equilibrium. Moreover, the proof of concept presented here suggests that protein metamorphosis is druggable, opening numerous avenues for controlling biological function of metamorphic proteins by altering the population of their multiple native states.

Evolution of fold switching in a metamorphic protein

Metamorphic protein folding as evolutionary adaptation

Specific binding-induced modulation of the XCL1 metamorphic equilibrium

Many dissimilar protein domains switch between α-helix and β-sheet folds

Crowded environments tune the fold-switching in metamorphic proteins

Distinguishing features of fold‐switching proteins

Global Fold Switching of the RafH Protein: Diverse Structures with a Conserved Pathway

Metamorphic proteins: the Janus proteins of structural biology

Lymphotactin: how a protein can adopt two folds

Switchable Membrane Remodeling and Antifungal Defense by Metamorphic Chemokine XCL1.

The Folding Transition State of Protein L is Extensive with Nonnative Interactions (and Not Small and Polarized)

Many dissimilar NusG protein domains switch between α-helix and β-sheet folds

Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1

Even With Nonnative Interactions, The Updated Folding Transition States Of The Homologs Proteins G & L Are Extensive And Similar

Cooperative "folding transition" in the sequence space facilitates function-driven evolution of protein families

The conformational landscape of fold-switcher KaiB is tuned to the circadian rhythm timescale

Sequence-Based Prediction of Metamorphic Behavior in Proteins

The role of evolutionary selection in the dynamics of protein structure evolution

Structural Analysis of a Metamorphic Protein using AlphaFold2

Simulating Protein Fold Switching by Replica-Exchange-with-Tunneling.

Kinetic and Thermodynamic Studies Reveal Chemokine Homologues CC11 and CC24 with an Almost Identical Tertiary Structure Have Different Folding Pathways.